Meytal Guller, Dylan J Cooper, Hosam Alkhatib, Aditya Suru, Angelo Blancaflor, Christopher A Maroun, Tristan Tham, Hailey Allen, Eden Mazzara, Jerin Thomas, Neha Amin, Evan Wu, David W Eisele, Carole Fakhry, Drew Pardoll, Tanguy Y Seiwert, Gangcai Zhu, Rajarsi Mandal
OBJECTIVES: To explore the impact of pre-existing comorbidities on immunotherapy response, overall and progression-free survival, and immune-related adverse events (irAEs) of patients with advanced head and neck cancer (HNC) treated with immunotherapy. PATIENTS AND METHODS: Ninety-three patients treated with immunotherapy were identified and stratified into comorbidity absent or present (CCI < 1 and CCI ≥ 1, respectively) cohorts, and clinical outcomes were compared between these two groups...
September 8, 2023: Head & Neck